Trial Profile
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2019
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms OTIVACTO
- Sponsors Boehringer Ingelheim
- 17 Sep 2018 According to a Boehringer Ingelheim media release, Professor Arschang Valipour was Lead Investigator for the OTIVACTO trial.
- 17 Sep 2018 According to a Boehringer Ingelheim media release, data from the trial presented at the European Respiratory Society (ERS) International Congress 2018.
- 17 Sep 2018 Results (n=7443) published in the Boehringer Ingelheim Media Release